Literature DB >> 2453705

[Bag plasmapheresis in patients with stage IIb peripheral arterial occlusive disease].

H Kiesewetter1, J Blume, F Jung, M Gerhards, S Spitzer, G Leipnitz, E Wenzel.   

Abstract

The clinical effect of bag-plasmapheresis was investigated in 60 patients with peripheral arterial occlusive disease stage II according to Fontaine. The initial number of patients was subdivided in three groups of 20 individuals using a randomised double-blind placebo-controlled design. Each patient gave 300 ml of blood twice a week for a 6 week duration. Blood plasma was separated in two groups and replaced with Hydroxyethyl-starch (200/0.5 10%) in group 1 and with Laevulose 5% in group 2. Patients in group 3 received their whole blood without any processing. All patients had to undergo a physical training of 45 minutes three times a week. The group who received Hydroxyethylstarch presented a 20% increase in walking distance whereas the increase in the Laevulose group was 5% and approximately 1% in the group receiving whole blood. The increase in walking distance in the Hydroxyethylstarch-group was significant on the 0.1%-level and significantly better than the improvement in walking distance of the other groups. Additionally in this group plasma viscosity showed a 3% decrease, erythrocyte aggregation was reduced by 10%. Results in the Laevulose group were only half as good as in the Hydroxyethylstarch group while parameters remained unchanged in the whole-blood-group. Bag plasmapheresis with Hydroxyethylstarch as substitute leads to an improvement in the walking capacity and blood fluidity thus offering a promising therapy for peripheral vascular occlusive disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2453705     DOI: 10.1007/bf01727513

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  12 in total

1.  Treatment of Waldenstrom's macroglobulinemia by plasmapheresis.

Authors:  P J SCHWAB; J L FAHEY
Journal:  N Engl J Med       Date:  1960-09-22       Impact factor: 91.245

2.  [Rapid physiological coagulation method in determination of fibrinogen].

Authors:  A CLAUSS
Journal:  Acta Haematol       Date:  1957-04       Impact factor: 2.195

3.  Recommendations concerning the collection of reference values in clinical chemistry and activity report by the Committee on Reference Values of the Scandinavian Society for Clinical Chemistry and Clinical Physiology.

Authors:  T Alström; R Gräsbeck; M Hjelm; S Skandsen
Journal:  Scand J Clin Lab Invest Suppl       Date:  1975

4.  [Isovolemic hemodilution in stage-IIb peripheral arterial occlusive diseases. Prospective randomized double-blind comparison of middle-molecule hydroxyethyl starch and electrolyte solution].

Authors:  H Kiesewetter; F Jung; J Blume; M Gerhards
Journal:  Dtsch Med Wochenschr       Date:  1986-08-29       Impact factor: 0.628

5.  [Determination of reference ranges of rheologic parameters: study of 653 randomly selected probands of the Aachen district].

Authors:  F Jung; H Kiesewetter; H G Roggenkamp; H P Nüttgens; E B Ringelstein; M Gerhards; G Kotitschke; E Wenzel; H Zeller
Journal:  Klin Wochenschr       Date:  1986-04-15

6.  [The capillary tube plasma viscosimeter. A new apparatus for measuring plasma viscosity].

Authors:  F Jung; H G Roggenkamp; R Schneider; H Kiesewetter
Journal:  Biomed Tech (Berl)       Date:  1983-11       Impact factor: 1.411

7.  [The mini-erythrocyte aggregometer: a new apparatus for the rapid quantification of the extent of erythrocyte aggregation].

Authors:  H Kiesewetter; H Radtke; R Schneider; K Mussler; A Scheffler; H Schmid-Schönbein
Journal:  Biomed Tech (Berl)       Date:  1982-09       Impact factor: 1.411

8.  [Predictor function of hemorheologic parameters with reference to the incidence of manifest circulatory disorders: Concept of the Aachen study].

Authors:  H Kiesewetter; F Jung; K H Ladwig; E Waterloh; P Roebruck; R Schneider; G Kotitschke; R Bach
Journal:  Klin Wochenschr       Date:  1986-07-15

9.  [Hemodilution in patients with stage IIb peripheral arterial occlusive disease: prospective randomized double-blind comparison of middle-molecular weight hydroxyethyl starch and low-molecular weight dextran solution].

Authors:  H Kiesewetter; F Jung; J Blume; M Gerhards
Journal:  Klin Wochenschr       Date:  1987-04-01

10.  [Middle-molecular hydroxyethyl starch as a volume substitute. Its rheological effect in peripheral arterial occlusive diseases].

Authors:  H Kiesewetter; J Blume; B Bulling; M Gerhards; F Jung; H Radtke; R P Franke
Journal:  Dtsch Med Wochenschr       Date:  1984-11-30       Impact factor: 0.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.